Compare Stanley Black & Decker, Inc. (SWK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs TransMedics Group Inc — how do they compare? Stanley Black & Decker, Inc. trades at $88.68 (market cap $13.47B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Stanley Black & Decker, Inc. is far larger — about 4.9× TransMedics Group Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and TransMedics Group Inc for 24 Days on average.
| SWK | TMDX | |
|---|---|---|
Market Cap | $13.47B | $2.74B |
Volume | 2,859,744 | 949,331 |
Sector | Industrials | Health |
52-Week High | $104.00 | $150.42 |
52-Week Low | $62.12 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $17.63B | $3.13B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $88.49, up 0.2% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89. Recent news highlights new product launches and dividend consistency as a Dividend King.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness. The consensus price target of $93.00 suggests 5% upside potential, but investors face execution risks amid competitive pressures and ongoing operational challenges. The stock's dividend history provides income stability while awaiting fundamental improvements.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
